Table 3 COVID-19 cases reported in female patients with FD
From: COVID-19 in Fabry disease: a reference center prospective study
Patient | Age (years) | FD genotype and phenotype | ERT (type, years) | FD risk factors (Risk category) | Non-FD related risk factors | COVID-19 manifestations | COVID-19 severity according to WHO | COVID-19 management | Acute COVID-19 duration (days) | Long-COVID-19 (duration and symptoms) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
8 a | 32 | p.M42T/Classic | Agalsidase-α, 16y | None (RC A) | Asthma under treatment | Hheadache, loss of appetite, myalgias, arthralgias, fatigue | Mild | Ibuprofen and Paracetamol | 3–5 | None | Recovered |
9 a | 68 | p.C172R/ Classic | Agalsidase-α, 18y | CKD-StI LVH arrhythmias: pacemaker and anticoagulation (RC B) | Smoking (past) COPD Gold Stadium II Mmoderate sleep apnoea | 3-day fever up to 38.3 C, 1.5 days productive cough, myalgias, fatigue | Mild | Paracetamol | 4–6 | None | Recovered |
10 a | 39 | Functional null allele due to splice site mutation/Classic (Hypermobile Ehlers-Danlos-like syndrome) | Agalsidase-α, 10y | None (RC A) | Ssocial alcohol consumption | Hheadache, dry cough, abdominal acke, dizziness, Fabry pain crisis | Mild | Eemergency department: single morphine administration | 14 | 6-months: fatigue, dry cough and dyspnoea in movement, more frequent pain crisis | Recovered |
11 b | 31 | p.I317T/Classic | Agalsidase-β, 2y | None (RC A) | None | None | Asymptomatic | None | 0 | None | Recovered |
12 b | 21 | p.S345P/ Classic | Agalsidase-β, 10y | CKD-StI (RC A) | Smoking (past) | None | Asymptomatic | None | 0 | None | Recovered |
13 a,b | 46 | p.T412SfsX38/Classic | Agalsidase-α, 16y | CKD-StI, Arrhythmias (RC B) | Overweight Smoking (current) Hypercholesterinemia Depression | Myalgias | Mild | Paracetamol | 10–12 | None | Recovered |